Patents by Inventor Eric H. Holmes
Eric H. Holmes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220403046Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to Fucosyl-GM1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting Fucosyl-GM1, as well as methods for treating various diseases, including cancer, using anti-Fucosyl-GM1 antibodies.Type: ApplicationFiled: August 5, 2022Publication date: December 22, 2022Applicant: E. R. SQUIBB & SONS, L.L.C.Inventors: Cynthia A. VISTICA, Eric H. HOLMES, Peter BRAMS, Alison WITTE, Josephine M. CARDARELLI
-
Publication number: 20190315881Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to Fucosyl-GM1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting Fucosyl-GM1, as well as methods for treating various diseases, including cancer, using anti-Fucosyl-GM1 antibodies.Type: ApplicationFiled: May 17, 2019Publication date: October 17, 2019Inventors: Cynthia A. VISTICA, Eric H. Holmes, Peter Brams, Alison Witte, Josephine M. Cardarelli
-
Publication number: 20170190785Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to Fucosyl-GM1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting Fucosyl-GM1, as well as methods for treating various diseases, including cancer, using anti-Fucosyl-GM1 antibodies.Type: ApplicationFiled: March 17, 2017Publication date: July 6, 2017Inventors: Cynthia A. VISTICA, Eric H. Holmes, Peter Brams, Alison Witte, Josephine M. Cardarelli
-
Patent number: 9631025Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to Fucosyl-GM1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting Fucosyl-GM1, as well as methods for treating various diseases, including cancer, using anti-Fucosyl-GM1 antibodies.Type: GrantFiled: August 13, 2015Date of Patent: April 25, 2017Assignee: E. R. SQUIBB & SONS, L.L.C.Inventors: Cynthia A. Vistica, Eric H. Holmes, Peter Brams, Alison Witte, Josephine M. Cardarelli
-
Publication number: 20160024221Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to Fucosyl-GM1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting Fucosyl-GM1, as well as methods for treating various diseases, including cancer, using anti-Fucosyl-GM1 antibodies.Type: ApplicationFiled: August 13, 2015Publication date: January 28, 2016Inventors: Cynthia A. VISTICA, Eric H. Holmes, Peter Brams, Alison Witte, Josephine M. Cardarelli
-
Patent number: 9138475Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to Fucosyl-GM1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting Fucosyl-GM1, as well as methods for treating various diseases, including cancer, using anti-Fucosyl-GM1 antibodies.Type: GrantFiled: January 22, 2013Date of Patent: September 22, 2015Assignee: E. R. Squibb & Sons, L.L.C.Inventors: Cynthia A. Vistica, Eric H. Holmes, Peter Brams, Alison Witte, Josephine M. Cardarelli
-
Patent number: 8383118Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to Fucosyl-GM1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting Fucosyl-GM1, as well as methods for treating various diseases, including cancer, using anti-Fucosyl-GM1 antibodies.Type: GrantFiled: December 8, 2006Date of Patent: February 26, 2013Assignee: Medarex, Inc.Inventors: Cynthia A. Vistica, Eric H. Holmes, Peter Brams, Alison Witte, Josephine M. Cardarelli
-
Publication number: 20100297138Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to Fucosyl-GM1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting Fucosyl-GM1, as well as methods for treating various diseases, including cancer, using anti-Fucosyl-GM1 antibodies.Type: ApplicationFiled: December 8, 2006Publication date: November 25, 2010Inventors: Cynthia A. Vistica, Eric H. Holmes, Peter Brams, Alison Witte, Josephine M. Cardarelli
-
Patent number: 7476513Abstract: The present invention relates to monoclonal antibodies that bind to the extracellular domain of prostate-specific membrane antigen (PSMA), hybridoma cell lines producing the antibodies, and methods of using such antibodies for diagnosis and treatment of cancer. In particular, thirty-five monoclonal antibodies reactive with PSMA expressed on the cell surface are exemplified. Additionally, the present invention relates to a novel protein variant (PSM?) of PSMA detected by a number of the antibodies of the invention. The hydrolase activity of PSMA and PSM? allows the use of an immunoenzymatic assay for their detection.Type: GrantFiled: June 9, 2005Date of Patent: January 13, 2009Assignee: Medarex, Inc.Inventors: Gerald P. Murphy, Alton L. Boynton, Eric H. Holmes, William T. Tino
-
Patent number: 7381407Abstract: The present invention relates to monoclonal antibodies that bind to the extracellular domain of prostate-specific membrane antigen (PSMA), hybridoma cell lines producing the antibodies, and methods of using such antibodies for diagnosis and treatment of cancer. In particular, thirty-five monoclonal antibodies reactive with PSMA expressed on the cell surface are exemplified. Additionally, the present invention relates to a novel protein variant (PSM?) of PSMA detected by a number of the antibodies of the invention. The hydrolase activity of PSMA and PSM? allows the use of an immunoenzymatic assay for their detection.Type: GrantFiled: April 28, 2000Date of Patent: June 3, 2008Assignee: Medarex, Inc.Inventors: Gerald P. Murphy, Alton L. Boynton, Eric H. Holmes, William Thomas Tino
-
Patent number: 7201900Abstract: The present invention relates to monoclonal antibodies that bind to the extracellular domain of prostate-specific membrane antigen (PSMA), hybridoma cell lines producing the antibodies, and methods of using such antibodies for diagnosis and treatment of cancer. In. particular, thirty-five monoclonal antibodies reactive with PSMA expressed on the cell surface are exemplified. Additionally, the present invention relates to a novel protein variant (PSM?) of PSMA detected by a number of the antibodies of the invention. The hydrolase activity of PSMA and PSM? allows the use of an immunoenzymatic assay for their detection.Type: GrantFiled: May 1, 2003Date of Patent: April 10, 2007Assignee: Medarex, Inc.Inventors: Gerald P. Murphy, Alton L. Boynton, Eric H. Holmes, William T Tino
-
Patent number: 6962981Abstract: The present invention relates to monoclonal antibodies that bind to the extracellular domain of prostate-specific membrane antigen (PSMA), hybridoma cell lines producing the antibodies, and methods of using such antibodies for diagnosis and treatment of cancer. In particular, thirty-five monoclonal antibodies reactive with PSMA expressed on the cell surface are exemplified. Additionally, the present invention relates to a novel protein variant (PSM?) of the PSMA detected by a number of the antibodies of the invention. The hydrolase activity of PSMA and PSM? allows the use of an immunoenzymatic assay for their detection.Type: GrantFiled: April 28, 2000Date of Patent: November 8, 2005Assignee: Medarex, Inc.Inventors: Gerald P. Murphy, Alton L. Boynton, Eric H. Holmes, William Thomas Tino
-
Nucleic acids and proteins of a rat ganglioside GM1-specific ?1-2fucosyltransferase and uses thereof
Patent number: 6936448Abstract: A rat ganglioside GM1-specific ?1?2fucosyltransferase is disclosed. Nucleotide sequences of a rat ganglioside GM1-specific ?1?2fucosyltransferase, amino acid sequences of its encoded protein (including peptide or polypeptide), and derivatives thereof are described. Also described are fragments (and derivatives and analogs thereof) which comprise a domain of rat ganglioside GM1-specific ?1?2fucosyltransferase with catalytic activity. Methods of production of rat ganglioside GM1-specific ?1?2fucosyltransferase and derivatives and analogs thereof (e.g. by recombinant means) are provided. Methods of inhibiting the function of rat ganglioside GM1-specific ?1?2fucosyltransferase (e.g. by means of antisense RNA) are provided. Methods of commercial scale use of the rat ganglioside GM1-specific ?1?2fucosyltransferase in the production of fucosyl-saccharide compositions are described. Applications of these compositions, e.g. as additives for human nutritive compositions or immunotherapeutics for cancer, are disclosed.Type: GrantFiled: November 1, 2001Date of Patent: August 30, 2005Assignee: Northwest Biotherapeutics, Inc.Inventors: Eric H. Holmes, Anne L. Sherwood -
Patent number: 6900291Abstract: The present invention relates to methods and materials for the detection and quantitation 8-OH-Ade in biological specimens. Specifically, the present invention is directed to a group of highly specific monoclonal antibodies reactive with the modified nucleoside structure 8-OH-Ade, and to various immunoassays for 8-OH-Ade utilizing these monoclonal antibodies. The monoclonal antibodies of the present invention may be used in assays for diagnosing or monitoring the progression of certain types of cancer, in addition to a variety of other diseases associated with mutagenesis resulting from oxidative damage of DNA. Assays utilizing the monoclonal antibodies of the present invention may also be used to analyze or monitor toxicant exposure, such as from environmental sources. The monoclonal antibodies of the present invention were prepared with the immunogen 8-OH-adenosine coupled to keyhole limpet hemocyanin (KLH), not to 8-OH-Ade directly.Type: GrantFiled: February 25, 2003Date of Patent: May 31, 2005Assignee: CytoChem, Inc.Inventors: Eric H. Holmes, Thomas G. Greene
-
Publication number: 20040024188Abstract: The present invention relates to monoclonal antibodies that bind to the extracellular domain of prostate-specific membrane antigen (PSMA), hybridoma cell lines producing the antibodies, and methods of using such antibodies for diagnosis and treatment of cancer. In. particular, thirty-five monoclonal antibodies reactive with PSMA expressed on the cell surface are exemplified. Additionally, the present invention relates to a novel protein variant (PSM′) of PSMA detected by a number of the antibodies of the invention. The hydrolase activity of PSMA and PSM′ allows the use of an immunoenzymatic assay for their detection.Type: ApplicationFiled: May 1, 2003Publication date: February 5, 2004Applicant: Northwest Biotherapeutics, Inc.Inventors: Gerald P. Murphy, Alton L. Boynton, Eric H. Holmes, William Thomas Tino
-
Patent number: 6656714Abstract: A rat ganglioside GM1-specific &agr;1→2fucosyltransferase is disclosed. Nucleotide sequences of a rat ganglioside GM1-specific &agr;1→2fucosyltransferase, amino acid sequences of its encoded protein (including peptide or polypeptide), and derivatives thereof are described. Also described are fragments (and derivatives and analogs thereof) which comprise a domain of rat ganglioside GM1-specific &agr;1→2fucosyltransferase with catalytic activity. Methods of production of rat ganglioside GM1-specific &agr;1→2fucosyltransferase and derivatives and analogs thereof (e.g. by recombinant means) are provided. Methods of inhibiting the function of rat ganglioside GM1-specific &agr;1→2fucosyltransferase (e.g. by means of antisense RNA) are provided. Methods of commercial scale use of the rat ganglioside GM1-specific &agr;1→2fucosyltransferase in the production of fucosyl-saccharide compositions are described. Applications of these compositions, e.g.Type: GrantFiled: October 31, 2001Date of Patent: December 2, 2003Assignee: Northwest HospitalInventors: Eric H. Holmes, Anne L. Sherwood
-
Publication number: 20030186344Abstract: The present invention relates to methods and materials for the detection and quantitation 8-OH-Ade in biological specimens. Specifically, the present invention is directed to a group of highly specific monoclonal antibodies reactive with the modified nucleoside structure 8-OH-Ade, and to various immunoassays for 8-OH-Ade utilizing these monoclonal antibodies. The monoclonal antibodies of the present invention may be used in assays for diagnosing or monitoring the progression of certain types of cancer, in addition to a variety of other diseases associated with mutagenesis resulting from oxidative damage of DNA. Assays utilizing the monoclonal antibodies of the present invention may also be used to analyze or monitor toxicant exposure, such as from environmental sources. The monoclonal antibodies of the present invention were prepared with the immunogen 8-OH-adenosine coupled to keyhole limpet hemocyanin (KLH), not to 8-OH-Ade directly.Type: ApplicationFiled: February 25, 2003Publication date: October 2, 2003Applicant: CytoChem, Inc.Inventors: Eric H. Holmes, Thomas G. Greene
-
Publication number: 20020137165Abstract: A rat ganglioside GM1-specific &agr;1→2fucosyltransferase is disclosed. Nucleotide sequences of a rat ganglioside GM1-specific &agr;1→2fucosyltransferase, amino acid sequences of its encoded protein (including peptide or polypeptide), and derivatives thereof are described. Also described are fragments (and derivatives and analogs thereof) which comprise a domain of rat ganglioside GM1-specific &agr;1→2fucosyltransferase with catalytic activity. Methods of production of rat ganglioside GM1-specific &agr;1→2fucosyltransferase and derivatives and analogs thereof (e.g. by recombinant means) are provided. Methods of inhibiting the function of rat ganglioside GM1-specific &agr;1→2fucosyltransferase (e.g. by means of antisense RNA) are provided. Methods of commercial scale use of the rat ganglioside GM1-specific &agr;1→2fucosyltransferase in the production of fucosyl-saccharide compositions are described. Applications of these compositions, e.g.Type: ApplicationFiled: November 1, 2001Publication date: September 26, 2002Inventors: Eric H. Holmes, Anne L. Sherwood
-
Publication number: 20020127655Abstract: A rat ganglioside GM1-specific &agr;1→2fucosyltransferase is disclosed. Nucleotide sequences of a rat ganglioside GM1-specific &agr;1→2fucosyltransferase, amino acid sequences of its encoded protein (including peptide or polypeptide), and derivatives thereof are described. Also described are fragments (and derivatives and analogs thereof) which comprise a domain of rat ganglioside GM1-specific &agr;1→2fucosyltransferase with catalytic activity. Methods of production of rat ganglioside GM1-specific &agr;1→2fucosyltransferase and derivatives and analogs thereof (e.g. by recombinant means) are provided. Methods of inhibiting the function of rat ganglioside GM1-specific &agr;1→2fucosyltransferase (e.g. by means of antisense RNA) are provided. Methods of commercial scale use of the rat ganglioside GM1-specific &agr;1→2fucosyltransferase in the production of fucosyl-saccharide compositions are described. Applications of these compositions, e.g.Type: ApplicationFiled: October 31, 2001Publication date: September 12, 2002Inventors: Eric H. Holmes, Anne L. Sherwood
-
Patent number: 6383759Abstract: The present invention is directed to methods of detecting prostate cancer in a sample of a body fluid with prostate cell marker-specific and epithelial cell marker-specific antibodies as well as to kits comprising such antibodies for use in the detection of prostate cancer. The present invention is also directed to methods of detecting prostate cancer in a sample of a body fluid with prostate cell marker-specific and tumor associated marker-specific antibodies as well as to kits comprising such antibodies for use in the detection of prostate cancer.Type: GrantFiled: January 15, 1999Date of Patent: May 7, 2002Assignee: Gerald P. Murphy Cancer FoundationInventors: Gerald P. Murphy, Alton L. Boynton, Eric H. Holmes, Robert J. Barren, III